Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ending of its deal with Hims & Hers jeopardizes the healthcare platform's goal to lead the weight loss market.

Novo Nordisk is banking on its pen-filled device and insulin leadership in India to gain a strong market share despite competitor Eli Lilly’s early mover advantage, and future competition from cheaper generics.